新的氨基阿达曼坦衍生物作为mopox病毒F13包膜蛋白的抑制剂
Thaís de Fátima Silva Moraes1, Erik Vinicius de Sousa Reis1, Gabriela Aparecida Azevedo1
1Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil; PROSPERA Group, Grupo de Prospecção e Pesquisas em Resposta Imune e Antivirais, Departamento de Microbiologia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|November 8, 2025
概括
氨基阿达曼坦 (AMA) 衍生物对mpox病毒 (MPV) 具有强烈的抗病毒活性. 化合物3F2通过降低病毒标位和干扰病毒颗粒组装显示出显著的潜力,这表明它是一个有前途的mopox治疗候选者.
科学领域:
- 病毒学 病毒学
- 药用化学 医学化学
- 药物发现 药物发现 药物发现
背景情况:
- 由麻疹病毒 (MPV) 引起的Mopox是全球重要的健康问题.
- 目前mpox的治疗选择有限,需要开发新的抗病毒药物.
研究的目的:
- 评估阿米诺阿达曼坦 (AMA) 和其合成衍生物对MPV的体外活性.
- 研究活性化合物的作用机制并确定活性化合物的潜在分子标.
主要方法:
- 进行了体外抗病毒试验,以确定AMA衍生物对MPV的疗效.
- 计算了选择性指数 (SI) 和半最大抑制度 (IC50).
- 使用传输电子显微镜 (TEM) 可视化化合物对病毒颗粒形成的影响.
- 用分子对接和协同分析来确定潜在的分子目标.
主要成果:
- 所有测试的化合物都对MPV表现出显著的体外活性,SI值超过1500.
- 衍生品3F2显示出异常强度 (IC50=0.0264) 并降低病毒标位高达100倍.
- TEM分析显示,3F2显著抑制了MPV粒子组合.
- 对接和协同研究表明,3F2和tecovirimat可能具有共同的分子标,MPV F13脂酶.
结论:
- AMA及其衍生品,特别是3F2,对MPV具有强大的抗病毒活性.
- 由于其强大的抗病毒作用和干扰病毒组合,3F2显示为mopox治疗开发的有希望的配置.
- 需要进一步研究3F2作为潜在的mopox治疗方法.
相关概念视频
Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...


